New Entyvio Formulation – Given as Injection at Home – Leads to Crohn’s Remission After One Year, Takeda Announces

New Entyvio Formulation – Given as Injection at Home – Leads to Crohn’s Remission After One Year, Takeda Announces
Maintenance therapy with Entyvio's new formulation as a subcutaneous, or under-the-skin injection (SC) led more people with moderate-to-severe, active Crohn's disease (CD) to achieve clinical remission after one year, compared with those receiving a placebo, Phase 3 trial results showed.  Moreover, Takeda Pharmaceuticals' new SC formulation of Entyvio (vedolizumab) will allow patients to self-administer the regular maintenance treatment at home instead of going to the hospital.  The findings, from the Phase 3 VISIBLE 2 clinical trial (NCT02611817), were reported this month during an oral presentation at the 15th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Vienna, Austria.  The abstract describing the details of the presentation, “Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: Results of the VISIBLE 2 study,” was published in the Journal of Crohn's and Colitis. Entyvio works by blocking pro-inflammatory immune cells from accessing the gastrointestinal (GI) tract. It currently is approved as an intravenous (IV) therapy for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease who failed to respond to conventional therapies or other biological medicines. Those therapies and medicines — such as Humira (adalimumab), made by AbbVie — stop tumor necrosis factor, or TNF. TNF is a multifunctional protein that plays an important role in cell survival, but also causes inflammation in the body.  In its approved form, Entyvio is an IV, or into-the-vein therapy given every eight weeks. While it is effective, the "catch" for patients is that its administration requires a hospital or clinic visit. The new, so-called SC formulatio
Subscribe or to access all post and page content.